Sumatriptan

When ATH:
N02CC01

Characteristic.

Selective agonist of 5-HT₁-receptors. White or off-white powder, easily soluble in water and saline.

Pharmacological action.
Protivomigrenoznoe.

Application.

Relief of migraine attacks (with or without aura).

Contraindications.

Hypersensitivity, hemiplegic, or basilar migraine oftalmoplegicheskaya form, myocardial infarction (incl. history), uncontrolled hypertension, CHD (incl. She suspected), angina, incl. Prinzmetal angina, occlusive peripheral vascular disease, transient ischemic attack (incl. history), stroke (incl. history), severely impaired liver and / or kidney, concomitant use of sumatriptan with ergotamine or derivatives thereof (including methysergide), as well as the simultaneous reception of MAO inhibitors and the period up to 2 Weeks after their withdrawal.

Restrictions apply.

Epilepsy (incl. any state with a reduction in the threshold of convulsive readiness), arterial hypertension (Controlled), pregnancy, lactation, Age to 18 years (Safety and efficacy have not established), older than 65 years (limited experience in the application).

Pregnancy and breast-feeding.

When pregnancy is possible only in case of, if the expected benefit to the mother outweighs the potential risk to the fetus (adequate and well-controlled studies of the safety of use is not carried out). You should avoid breastfeeding during 24 hours after sumatriptan (It passes into breast milk).

Side effects.

Cardio-vascular system and blood (hematopoiesis, hemostasis): decrease in blood pressure, a temporary increase in blood pressure (observed shortly after administration), bradycardia, tachycardia (incl. Ventricular), heartbeat; in some cases - abnormal heart rhythm (until ventricular fibrillation), transient ischemic ECG changes such as, myocardial infarction, spasm of the coronary arteries; sometimes develops Raynaud's syndrome.

From the digestive tract: nausea and vomiting (usually by ingestion), slight increase in liver enzymes, dysphagia, abdominal discomfort; rarely, ischemic colitis.

From the nervous system and sensory organs: dizziness, weakness and / or tiredness (usually by ingestion), drowsiness (usually they are mild to moderate and transient in nature are); in some cases, convulsive seizures (usually in the presence of a history of seizures or conditions, predisposing to seizures); occasionally diplopia, flicker flies before his eyes, nistagmo, scotoma, reduced visual acuity; extremely rare — partial transient vision loss (impairment may be associated with a migraine attack itself).

Hypersensitivity reactions: cutaneous manifestations (rash, hives, itch, эritema); in rare cases, anaphylaxis.

Other: pain, pricking, feeling the heat, a feeling of pressure or heaviness (They are usually transient, but may be intense and occur in any part of body, including the chest and throat), myalgia, flushing.

Local symptoms (by intranasal application): slight transient irritation or burning sensation in the nose and / or throat, nose bleed.

Cooperation.

When concomitantly with ergotamine and medicines ergotaminsoderzhaschimi celebrated long vasospasm (sumatriptan can be administered no earlier than, than 24 hours after ingestion, containing ergotamine, and drugs, containing ergotamine, It can be administered no earlier than, than 6 hours after administration of sumatriptan). Interoperability between sumatriptan and MAOIs (their concurrent use is contraindicated). Interoperability between sumatriptan and drugs from the group of selective serotonin reuptake inhibitors (SSRIs). There was no interaction with propranolol sumatriptan, flunarizinom, pizotifenom and ethanol.

Overdose.

Treatment: monitor the status of the patient at least 10 no, If necessary, supportive therapy. No data on the effect of hemodialysis or peritoneal dialysis on plasma concentrations of sumatriptan.

Dosing and Administration.

Inside, intranasally, adult (18 and older). Inside- 50 mg (if necessary 100 mg). Intranasal — 20 mg (1 dose) in one nostril. Re-introduction may at intervals of not less than 2 no. The maximum daily dose of ingestion- 300 mg, by intranasal application - 2 dose on 20 mg.

Precautions.

Not intended for migraine prophylaxis. The appointment of the drug is possible only in the case, If the diagnosis is not in doubt. When assigning sumatriptan in patients with previously diagnosed with migraine or migraine patients with atypical necessary to exclude other potentially serious neurological condition (As with other funds protivomigrenoznyh). It should be taken into account, that migraine patients are at increased risk of cerebrovascular disorders (such as a stroke or transient ischemic attack).

The presence of risk factors to the cardiovascular system (in postmenopausal women, men over the age of 40 years and patients with risk factors for coronary heart disease) dictates the need for a preliminary examination in order to avoid cardiovascular disease.

It was reported on the development of weakness, hyperreflexia and incoordination after administration of sumatriptan and SSRIs (in the case of co-administration should carefully monitor the patient's condition).

Before and during treatment, you should regularly eat, diet, exclude products, containing tyramine (chocolate, cocoa, nuts, citrus, beans, tomatoes, celery, cheeses), and alcoholic beverages (incl. dry, especially red, wine, Champagne, beer), live a healthy life, do sport (swimming, skiing, walking), to have any hobby, which creates a positive emotional state, and thus prevents the occurrence of migraine attacks.

People with known hypersensitivity to sulfonamides history increased risk of allergic reactions. Be wary designate drivers of vehicles and persons, engaged in potentially hazardous activities, require attention and speed of reaction.

Cooperation